genes in addition to PLP1, but it is not known whether these other genes affect the disease phenotype. Size of the duplication does not correlate with clinical severity of the disease.
4, 5
Point mutations and indels (insertion or deletion of one to a few bases) of PLP1 account for 25% of PMD/SPG2 cases. 1 Point mutations that result in amino acid substitutions (missense mutations) have been reported throughout coding regions. Frameshift mutations that result in truncated protein or are null, and mutations that result in aberrant splicing are less common than missense mutations but have also been reported. [8] [9] [10] [11] Genomic triplication and higher copy numbers of PLP1, partial triplication, and complete and partial deletion are rare, but also result in PMD. 7, 12, 13 Reported mutations of the PLP1 gene are cataloged at http://www.ncbi.nlm.nih.gov/ books/NBK1182/. 14 PMD is a rare disease that is not limited to nationality or race. Incidence was reported to be 0.13 in 100,000 live births in Germany and 1 in 90,000 in the Czech Republic. 15, 16 The reason for the discrepant incidence numbers is unknown.
Pelizaeus-Merzbacher-Like Disease 1 and Spastic Paraplegia 44
When patients have symptoms of PMD but do not have mutations of PLP1, their disease is called Pelizaeus-Merzbacher-like disease (PMLD). 17 Only 8% of PMLD cases are caused by mutations of the gap junction protein, gamma-2 gene (GJC2, MIM #608803), formerly known as the gap junction protein, α-12 gene (GJA12). GJC2 encodes a member of a large family of connexin proteins. Like PLP, the gap junction protein gamma-2, also called connexin 47 (Cx47) or connexin 46.6 (Cx46.6), encoded by the GJC2 gene is a 4-pass transmembrane protein with two extracellular and three intracellular domains. PMLD caused by GJC2 mutations is called PMLD1 (MIM #608804), or leukodystrophy hypomyelinating 2 (HDL2). Molecular etiology of the remaining cases of PMLD is unknown. PMLD1 is inherited as an autosomal recessive trait, affecting males and females with equal frequency. Patients with PMLD1 have homozygous or compound heterozygous mutations. [18] [19] [20] [21] [22] [23] Missense, nonsense, frameshift, and indel mutations have been reported. A mutation in the promoter of GJC2 was also reported to cause PMLD1.
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Five patients with PMLD were reported to have only one mutation of the GJC2 gene, leaving their disease not fully explained at the molecular level. 22 A milder disease, spastic paraplegia 44 (SPG44), was reported in one family with individuals who have a homozygous mutation of GJC2.
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Incidence of PMLD1 and SPG44 has not been reported. It should be noted that mutations of the GJC2 gene have also been reported to cause autosomal dominant lymphedema. Early signs suggestive of PMD that are present at birth or in the first few months of life include nystagmus and hypotonia, and in the more severe cases there may be stridor, sometimes with vocal cord paralysis, feeding difficulty, and seizures. Subsequently, developmental milestones are delayed. By around 6 months or later, ataxia of the limbs becomes apparent and over several years, the limb hypotonia is replaced by spasticity of the limbs. Dystonic posturing and athetotic movements may be present, and cognitive impairment is present in most children. The cognitive delay often leads to difficulty in clinical educational assessment. When sufficient time is given for children to respond to questions or instructions, they are often found to be more capable than they initially appear. Clinical phenotypes reported range from the severe so-called connatal form of PMD to the milder complicated and pure SPG2.
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Connatal PMD is observed at birth or in the first 2 weeks of life. Stridor and seizures are common in this form. Hypotonia in infancy evolves into severe spasticity during childhood. Patients do not develop the ability to walk, gain use of their upper extremities, or talk, although there may be comprehension of verbal language. Patients may have short stature and have poor weight gain. They often require gastrostomy feeding tubes for nutritional support. Dystonia may occur. Most children with connatal disease die in the first one to two decades of life.
Classic PMD is the phenotype originally described by Pelizaeus and Merzbacher. It is the most common phenotype because patients with duplication most frequently have classic PMD. Patients develop nystagmus, usually noticed within the first 2 months of life, but occasionally, patients do not develop nystagmus. It typically resolves within 2 to 5 years of age. Patients develop head titubation that may resolve. Hypotonia in infancy begins to evolve to spastic quadriplegia in the first 5 years. Patients usually develop purposeful use of the upper extremities and dysarthric language. At the milder end of the classic PMD range, patients may begin to walk in childhood, usually with an assistive device, but as spasticity becomes greater, they lose the ability to walk. Dystonia and athetosis may occur at the severe end of the classic PMD range. Seizures are rare. Lifespan may be shortened, but patients with classic PMD have lived to the seventh decade.
The PLP null phenotype occurs when no PLP protein is present and is typically a complicated SPG phenotype that develops in the first 1 to 5 years of life. It is characterized by mild to moderate developmental delay, spastic gait, and mild demyelinating peripheral neuropathy. 30 Over time, progression of signs after puberty is typical and ultimately leads to severe spastic quadriplegia, with loss of communication abilities. Complicated SPG2 begins in the first 5 years of life with nystagmus, ataxia, and autonomic dysfunction, such as spastic urinary bladder. Patients are able to walk with a spastic gait. Patients are able to talk, but speech may be slow. Lifespan may be normal.
Pure SPG2 is usually apparent in the first 5 years, but onset may be delayed until the third or fourth decade. Patients are able to walk with a spastic gait. Patients are able to talk, but speech may be slow. Lifespan is normal.
The wide clinical spectrum in PMD/SPG2 is a reflection of the diverse molecular etiology. Disease severity increases with increasing copy number of PLP1 and is not affected by the size of the duplicated region. 4, 5, 12 Duplications of the PLP1 gene usually result in classic PMD, while triplications are reported to cause a more severe phenotype. Complete deletion of the PLP1 gene and point mutations that disrupt the methionine codon or that cause truncation of the protein near the amino-terminus result in the milder null phenotype.
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Other point mutations (missense, frameshift, nonsense) and indels are reported to result in severity across the entire spectrum of PMD/SPG2 phenotypes. 11, 29 Mutations that affect the PLP-specific region and not the DM20 isoform result in disease toward the mild end of the spectrum, including spastic paraplegia phenotypes. 29 There can be some intrafamilial phenotypic heterogeneity. Children with PMD may not have definitively abnormal MRI scans until the age of 1 or 2 when rapid myelination is completed. However, absence of normal myelin-related changes in the pons and cerebellum of a newborn or absence of normal myelin-related changes in the posterior limb of the internal capsule, the splenium of the corpus callosum, and the optic radiations of a 3-month-old child could suggest PMD or other leukodystrophies. 38 It should be noted that T1-weighted images may be more sensitive to these early changes than T2-weighted images.
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Metabolite levels on magnetic resonance spectroscopy (MRS) are not necessarily consistent across the forms of PMD. Patients with duplications have increased levels of Nacetyl aspartate (NAA), 39 whereas patients with other mutations, especially those that lack PLP protein, have reduced NAA levels. 36, 40, 41 Most patients with point mutations or duplications have low levels of choline consistent with hypomyelination of PLP1, but increased levels of choline are seen in some cases, suggesting ongoing demyelination. 41 In PMD duplication patients, increased levels of glutamine, inositol, and creatine are seen on MRS in addition to increased NAA.
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This pattern is distinctive and may assist with distinguishing PMD from other leukodystrophies. The MRI of PMLD1 patients shows a diffuse pattern of hypomyelination, quite similar or indistinguishable from those of true PMD patients (see above). [17] [18] [19] [20] [21] 37 Sparing of the corticospinal tracts, as can occur in classical PMD, has been reported. However, unlike PMD patients, two PMLD1 patients had normal or almost normal levels of choline, NAA and creatine on MRS, suggesting that MRS might be useful in distinguishing PMD and PMLD1.
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Diagnosis and Testing of PMD/SPG2 and PMLD1/SPG44
Diagnosis of PMD/SPG2 is made based on clinical presentation, MRI indicative of diffusely abnormal myelin, X-linked inheritance pattern, and molecular testing indicating duplication or other mutation of the PLP1 gene. 27 Diagnosis of PMLD1/SPG44 is made based on clinical presentation, MRI indicative of diffusely abnormal myelin, autosomal recessive inheritance pattern, and molecular testing indicating mutations of the GJC2 gene.
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Brainstem auditory evoked potentials (BAEP) may be a helpful tool to distinguish between classic PMD and PMLD1.
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In one study, waves III, IV, and V generated in the pons and midbrain, were absent in 10 patients with PMD, but were present in 11 of 13 investigations in 8 patients with PMLD1.
Molecular Testing of Male Patients
When PMD is suspected clinically in male patients, PLP1 gene duplication testing is a reasonable first step because duplications are the most common PLP1 gene defect occurring in over 50% of the patients who fit strict clinical criteria for PMD. 1 The tests for duplication will also detect less common deletions. Several methods are currently in use by clinical diagnostic laboratories for duplication/deletion testing: quantitative multiplex polymerase chain reaction (PCR), multiple ligation probe analysis (MLPA), real time PCR, array comparative genomic hybridization (aCGH), and fluorescent in situ hybridization (FISH). Considerations and limitations for these methods are as follows:
• Quantitative multiplex PCR, MLPA, real time PCR, aCGH, and interphase FISH can detect copy number changes. These methods cannot be used to determine whether the duplication is tandem or inserted elsewhere in the genome. Tandem duplications that are smaller than 100 kilobases may not be resolved by interphase FISH.
• Most PMD duplications are too small to resolve by metaphase FISH. However, metaphase FISH can be used to determine location of duplicated segments that are inserted in a region of the genome that is distant from the PLP1 gene.
• Quantitative multiplex PCR, MLPA, and real-time PCR are generally designed to detect only copy number changes in the PLP1 gene itself. They do not give information about the extent of the region that is duplicated unless they are designed to do so.
• aCGH can give information about the extent of the region that is duplicated. Size and spacing of the probes on the array should be taken into consideration. When aCGH is performed with closely spaced oligonucleotide probes, it is more sensitive than when performed with larger probes such as BACs or cosmids. If probes are spaced too far apart on aCGH, false-negatives may result.
If duplication or deletion of the PLP1 gene is not detected in male patients, sequence analysis of the PLP1 gene is the next step. Mutations of PLP1 that can be detected by sequence analysis account for 25% of cases that fit strict clinical criteria for PMD.
1 Male patients who are negative for PLP1 mutations should next be tested for GJC2 mutations. Approximately 8% of PMLD patients (those who test negative for PLP1 duplications or other mutations) have mutations in the GJC2 gene. 22 However, the percentage of GJC2 mutations in consanguineous PMLD cases was 30%, suggesting that sequence analysis for GJC2 mutations prior to sequence analysis for PLP1 mutations might be justified in these cases. When a mild spastic paraplegia phenotype is determined clinically in male patients, it is reasonable to undertake DNA sequence analysis of the PLP1 gene prior to duplication analysis.
Molecular Testing of Female Patients
A reasonable approach for testing females who have clinical symptoms of PMD/PMLD in families with no affected male family members is to begin with sequence analysis for mutations of the GJC2 gene. Approximately 16% of females with PMLD had mutations of GJC2. 22 If an affected female tests negative for GJC2 mutations, then duplication analysis and sequence analysis of the PLP1 gene might be justified, especially if the phenotype is mild because carrier females in families with PLP1 duplications and mutations can be mildly affected.
Carrier Testing, Prenatal Testing, and Preimplantation Genetic Diagnosis for Family Members
Carrier testing for at-risk females and prenatal testing for atrisk pregnancies in PMD families require prior identification of the disease-causing mutation in a male family member. Preimplantation genetic diagnosis has been reported for point mutation of PLP1.
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Carrier testing for at-risk individuals and prenatal testing in PMLD1 families require prior identification of the diseasecausing alleles. Carrier testing for parents of patients with PMLD1 may help determine whether heterozygous individuals are compound heterozygotes (two mutations are on different alleles) and whether individuals with one mutation are homozygous or have a deletion of one allele. Preimplantation genetic diagnosis should be possible for PMLD1 families.
Other Considerations
When only one heterozygous GJC2 mutation is identified in a PMLD patient, the following may be considered: (1) the mutation may be unrelated to the disease in the patient; (2) the patient may have a second mutation in a region of the other GJC2 allele that was not sequenced, such as a transcriptional or splicing regulatory region; (3) the mutation in the patient may be causing autosomal dominant disease; and (4) the mutation detected may combine with mutation of a different gene to produce the disease phenotype (digenic inheritance). Both options 3 and 4 have been reported for gap junction protein genes that cause congenital deafness.
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Other diseases that may be considered when PMD/SPG2 and PMLD1/SPG44 mutations are not identified: 
